Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study

dc.contributor.authorSafreed-Harmon, Kelly
dc.contributor.authorHetherington, Kristina L.
dc.contributor.authorAleman, Soo
dc.contributor.authorAlho, Hannu
dc.contributor.authorDalgard, Olav
dc.contributor.authorFrisch, Tove
dc.contributor.authorGottfredsson, Magnus
dc.contributor.authorWeis, Nina
dc.contributor.authorLazarus, Jeffrey V.
dc.contributor.authorHep-Nordic Study Group
dc.date.accessioned2018-03-28T08:03:03Z
dc.date.available2018-03-28T08:03:03Z
dc.date.issued2018-01-30
dc.date.updated2018-02-28T18:59:52Z
dc.description.abstractBackground and aims: In the Nordic countries (Denmark, Finland, Iceland, Norway, Sweden), the prevalence of chronic hepatitis C virus (HCV) infection is relatively low in the general population, but is much higher among people who inject drugs (PWID). We conducted an exploratory study to investigate the extent to which these countries have policies supporting key elements of the public health response that is necessary to achieve the global goal of eliminating HCV as a public health threat. Methods: Fourteen stakeholders representing government agencies, medical societies, and civil society organisations (CSOs) in the Nordic countries completed a cross-sectional online survey that included 21 policy questions related to national coordination, prevention, testing, linkage to care, and treatment. We summarised the findings in a descriptive analysis, and noted discrepant responses from stakeholders within the same country. Results:Stakeholders reported that three of the five study countries have national viral hepatitis strategies, while only Iceland has a national HCV elimination goal. The availability of harm reduction services varies, with opioid substitution therapy provided for the general population throughout all countries, but not needle and syringe programmes. No country has access to anonymous HCV testing in all parts of the country. National HCV treatment guidelines are available in all countries except Finland, and all countries provide publicly funded direct-acting antiviral treatment. Disagreement regarding policies was observed across countries, and CSOs were the stakeholder group that most frequently answered survey questions incorrectly. Conclusion: The Nordic region as a whole has not consistently expressed its commitment to tackling HCV, despite the existence of large HCV epidemics among PWID in these countries. Stakeholder alignment and an established elimination goal with an accompanying strategy and implementation plan should be recognised as the basis for coordinated national public health efforts to achieve HCV elimination in the Nordic region and elsewhere.
dc.format.extent17 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn1932-6203
dc.identifier.pmid29381697
dc.identifier.urihttps://hdl.handle.net/2445/121180
dc.language.isoeng
dc.publisherPublic Library of Science (PLoS)
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0190146
dc.relation.ispartofPLoS One, 2018, vol. 13, num. 1, p. e0190146
dc.relation.urihttp://dx.doi.org/10.1371/journal.pone.0190146
dc.rightscc by (c) Safreed Harmon et al., 2018
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.sourceArticles publicats en revistes (ISGlobal)
dc.subject.classificationHepatitis C
dc.subject.classificationEscandinàvia
dc.subject.otherHepatitis C
dc.subject.otherScandinavia
dc.titlePolicy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
safreed-harmon2018_2894.pdf
Mida:
1.28 MB
Format:
Adobe Portable Document Format